China Pharma (CPHI) Competitors $1.82 -0.06 (-2.98%) Closing price 10/17/2025 03:59 PM EasternExtended Trading$1.83 +0.01 (+0.38%) As of 10/17/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock CPHI vs. ALVR, MTVA, NNVC, CASI, AYTU, MBRX, ALLR, PCSA, CTXR, and RLYBShould you be buying China Pharma stock or one of its competitors? The main competitors of China Pharma include AlloVir (ALVR), MetaVia (MTVA), NanoViricides (NNVC), CASI Pharmaceuticals (CASI), Aytu BioPharma (AYTU), Moleculin Biotech (MBRX), Allarity Therapeutics (ALLR), Heatwurx (PCSA), Citius Pharmaceuticals (CTXR), and Rallybio (RLYB). These companies are all part of the "pharmaceutical products" industry. China Pharma vs. Its Competitors AlloVir MetaVia NanoViricides CASI Pharmaceuticals Aytu BioPharma Moleculin Biotech Allarity Therapeutics Heatwurx Citius Pharmaceuticals Rallybio China Pharma (NYSE:CPHI) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings. Which has more volatility & risk, CPHI or ALVR? China Pharma has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Do insiders and institutionals have more ownership in CPHI or ALVR? 66.1% of AlloVir shares are held by institutional investors. 17.3% of China Pharma shares are held by company insiders. Comparatively, 32.1% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger earnings & valuation, CPHI or ALVR? China Pharma has higher revenue and earnings than AlloVir. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina Pharma$4.40M1.35-$3.08MN/AN/AAlloVirN/AN/A-$190.42M-$20.23-0.23 Is CPHI or ALVR more profitable? AlloVir has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat AlloVir's return on equity.Company Net Margins Return on Equity Return on Assets China Pharma-85.56% -63.93% -31.42% AlloVir N/A -71.03%-61.27% Does the media favor CPHI or ALVR? In the previous week, AlloVir had 1 more articles in the media than China Pharma. MarketBeat recorded 2 mentions for AlloVir and 1 mentions for China Pharma. AlloVir's average media sentiment score of 0.00 beat China Pharma's score of -1.00 indicating that AlloVir is being referred to more favorably in the news media. Company Overall Sentiment China Pharma Negative AlloVir Neutral SummaryChina Pharma and AlloVir tied by winning 5 of the 10 factors compared between the two stocks. Get China Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CPHI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CPHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPHI vs. The Competition Export to ExcelMetricChina PharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$5.95M$1.08B$6.15B$21.82BDividend YieldN/A4.84%5.72%3.62%P/E RatioN/A1.3085.7032.43Price / Sales1.3529.96612.9260.43Price / CashN/A17.6325.8218.06Price / Book2.618.0712.224.59Net Income-$3.08M-$7.36M$3.33B$1.01B7 Day Performance0.22%-1.73%1.17%1.31%1 Month Performance-8.11%28.41%6.85%-0.93%1 Year Performance-92.67%-12.09%58.93%9.51% China Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPHIChina Pharma0.1489 of 5 stars$1.82-3.0%N/A-92.4%$5.95M$4.40M0.00250Negative NewsShort Interest ↑ALVRAlloVirN/A$4.76+7.0%N/A-74.0%$24.01MN/A-0.24110News CoverageHigh Trading VolumeMTVAMetaVia1.6318 of 5 stars$1.02+2.9%$7.50+635.3%N/A$23.98MN/A0.008Gap DownNNVCNanoViricides0.8216 of 5 stars$1.35-0.7%N/A+2.0%$23.53MN/A-1.8720News CoverageShort Interest ↓CASICASI Pharmaceuticals3.5593 of 5 stars$1.81-4.2%$4.00+121.0%-68.9%$23.25M$31.56M-0.63180Analyst ForecastAYTUAytu BioPharma3.3018 of 5 stars$2.38+1.7%$9.17+285.2%+0.0%$23.19M$66.38M-0.84160Analyst ForecastMBRXMoleculin Biotech1.7009 of 5 stars$0.50+5.9%$4.00+708.1%-80.4%$23.14MN/A0.0020Gap DownALLRAllarity Therapeutics2.2089 of 5 stars$1.52-0.7%$9.25+508.6%-16.8%$22.22MN/A0.0010Gap DownPCSAHeatwurx2.4601 of 5 stars$0.40-10.2%$1.00+152.5%-77.5%$22.21MN/A-0.1720Negative NewsShort Interest ↑CTXRCitius Pharmaceuticals2.6366 of 5 stars$1.30flat$53.00+3,976.9%-85.2%$22.12MN/A0.0020News CoverageRLYBRallybio2.7976 of 5 stars$0.53+1.3%$5.00+834.9%-52.2%$22.07M$761K-0.5740Gap Down Related Companies and Tools Related Companies AlloVir Competitors MetaVia Competitors NanoViricides Competitors CASI Pharmaceuticals Competitors Aytu BioPharma Competitors Moleculin Biotech Competitors Allarity Therapeutics Competitors Heatwurx Competitors Citius Pharmaceuticals Competitors Rallybio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CPHI) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China Pharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.